 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Long-term (15 years) prognosis of early breast cancer with a single intraoperative radiotherapy

Lancet Oncol: Long-term (15 years) prognosis of early breast cancer with a single intraoperative radiotherapy

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

treatment

center veterinary medicine

1 4 dilution

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Radiotherapy continues to play an important role in the treatment of early breast cancer , which can reduce the overall recurrence rate and mortality of patients.

Breast Cancer For patients with early breast cancer, compared with whole breast radiotherapy (WBI), accelerated local breast radiotherapy (APBI) with intraoperative radiotherapy is associated with a higher rate of recurrence of ipsilateral breast tumors (IBTR)

Recently published in The Lancet sub-Journal " Lancet Oncolog on y" article " Intraoperative irradiation for Early Breast Cancer (ELIOT): Long-Term Recurrence and Survival Outcomes from A SINGLE-Center, randomized, Phase 3 Trial an EQUIVALENCE ", The long-term recurrence rate and survival prognosis of patients in the ELIOT trial were evaluated .

The Lancet Oncolog Lancet Oncolog Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial evaluated the long-term recurrence rate and survival prognosis of patients in the ELIOT trial

The ELIOT trial is a single-center, randomized phase 3 trial carried out in Italy.

From November 20, 2000 to December 27, 2007, a total of 1305 patients were recruited, of which 654 were assigned to the WBI group and 651 were assigned to the ELIOT group.

Cumulative incidence of IBTR in both groups

After a median follow-up of 12.

IBTR occurred in 86 patients (7%), of which 70 (11%) were in the ELIOT group and 16 (2%) were in the WBI group.

There was no significant difference in mortality between the two groups

Overall survival rate of the two groups

In the ELIOT group, the overall survival rates at 5, 10, and 15 years were 96.

The long-term results of the trial confirmed that the IBTR rate of the ELIOT group was significantly higher than that of the WBI group, but there was no significant difference in overall survival rate.

Original source:

Orecchia Roberto, Veronesi Umberto, Maisonneuve Patrick et al.

org/10.
1016/S1470-2045(21)00080-2" target="_blank" rel="noopener">Intraoperative irradiation for early breast cancer (ELIOT ): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.